The Activities. The Group and the Company shall perform the activities in accordance with the Scope of Work, Exhibit A, for the clinical trial E2112 (EA1122) “A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Post-menopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer” (the “Study”). The principal investigator (the “Principal Investigator”) for the Group is ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, M.D., assisted by ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, MB, BCh., the study chair (“Study Chair”) for the Protocol. The Group shall use reasonable efforts to carry out the Study as set forth in the current clinical trial protocol for the Study (the “Protocol”) and in accordance with this Agreement.
Appears in 3 contracts
Sources: Clinical Trial Agreement (Syndax Pharmaceuticals Inc), Clinical Trial Agreement (Syndax Pharmaceuticals Inc), Clinical Trial Agreement (Syndax Pharmaceuticals Inc)